


FORM PTO-1449 (Modified)		Attorney Docket No.: 15280-3770		Application No.: 09/267,511	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Brenneman et al.		Filing Date: March 12, 1999	
		Group: 1643			
Reference Designation		U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class
AA	5,767,240	06/16/98	Brenneman et al.	530	350
Filing Date: 4/22/92					
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class
AB	WO 92/18140	10/29/92	PCTO	A61K	37/00
AC	WO 96/11948	04/25/96	PCT	C07K	14/475
AD	WO 98/35042	08/13/98	PCT	C12N	15/18
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AE	Bassan, M. et al. "VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein." <i>Regulatory Peptides</i> , 71(2):, August 15, 1997.				
AF	Bassan, M. et al. "Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide." <i>Journal of Neurochemistry</i> 72:1283-1293 (1999)				
AG	Beni-Adani, L. et al. "Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury." Society for Neuroscience, 28 <sup>th</sup> Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> 23(1):1043 (1998).				
AH	Brenneman, D.C. and Gozes, I. "A Femtomolar-Acting Neuroprotective Peptide." <i>Journal of Clinical Investigation</i> 97:229-230 (1996)				
AI	Brenneman, D.E. et al. "Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2): 2250 (1997).				
AJ	Brenneman, D.E. et al. "Activity-Dependent neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides." <i>Journal of Pharmacology and Experimental Therapeutics</i> 285: 619-627 (1998)				
AK	Davidson, A. et al. "Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2)2250 (1997).				
AL	Dibbern, D.A., Jr. et al. "Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor." <i>Journal of Clinical Investigation</i> 99: 2837-2841 (1997)				
AM	Giladi, E. "Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." <i>Neuroscience Letters</i> Supplement 48 S1-S60, P. S19 (1997).				
AN	Glazner, G.W. et al. "A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2)2249 (1997).				
AO	Gozes, I. et al. "Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment." <i>Endocrinology</i> 134: 2125 (1994).				
AP	Gozes, I. et al. "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors." <i>Journal of Pharmacology and Experimental Therapeutics</i> 27:3161-167 (1995).				
AQ	Gozes, I. et al. "Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide." <i>Proc. Natl. Acad. Sci. USA</i> 93:427-432 (1996).				
AR	Gozes, I. and Brenneman, D.E. "Activity-Dependent Neurotrophic Factor (ADNF)." <i>Journal of Molecular Neuroscience</i> 7:235-244 (1996).				
EXAMINER	DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)				Attorney Docket No.: 15280-3770		Application No.: 09/267,511	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Brenneman et al.			
				Filing Date: March 12, 1999		Group: 1643	
Reference Designation				U.S. PATENT DOCUMENTS		Page 2	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)	
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<u>85</u> AS	Gozes, I. <i>et al.</i> "Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease." <i>Journal of Neurobiology</i> 33:329-342 (1997).						
<u>85</u> AT	Gozes I. <i>et al.</i> "Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity." <i>Developmental Brain Research</i> 99:167-175 (1997).						
<u>85</u> AU	Gozes, I. <i>et al.</i> "The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent Neurotrophic Factor III (ADNFIII)." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2250 (1997).						
<u>85</u> AV	Gozes, I. <i>et al.</i> "A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP). <i>Neuroscience Letters</i> Supplement 48 S1-S60, p. S21 (1997)-						
<u>85</u> AW	Hill, J.M. <i>et al.</i> "Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiserum to Activity-Dependent Neurotrophic Factor (ADNF)." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2250 (1997).						
<u>85</u> AX	Lilling, G. <i>et al.</i> "Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist." <i>Journal of Molecular Neuroscience</i> 5: 231-239 (1995).						
<u>85</u> AY	McKune, S.K. <i>et al.</i> "Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2249 (1997)						
<u>85</u> AZ	Nelbock, P. <i>et al.</i> "A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator. <i>Science</i> , 248:1650-1653 (1990).						
<u>85</u> AAA	Pelsman, A. <i>et al.</i> "In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides." Society for Neuroscience, 28 <sup>th</sup> Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> 24:1044 (1998)						
<u>85</u> AAB	Brenneman <i>et al.</i> "Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide." <i>Nature</i> 335:636 (1988).						
<u>85</u> AAC	Brenneman <i>et al.</i> "N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures" <i>Dev. Brain Res.</i> 51:63 (1990).						
<u>85</u> AAD	Glazner, G.W. <i>et al.</i> "Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth." <i>Anat. Embryol.</i> 200:65-71 (1999).						
<u>85</u> AAE	Gressens, P. <i>et al.</i> "Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos." <i>Nature</i> , 362:155-58 (1993).						
EXAMINER		<u>S. J. J.</u>		DATE CONSIDERED		<u>10-16-00</u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.